Advances in diabetes treatment and management
- Submission status
- Closed
- Submission deadline
Diabetes continues to present a major global healthcare burden. While recent years have seen the advancement of strategies for type 2 diabetes prevention strategies through lifestyle interventions, treatment and management of established disease remains complex, though new advances in glucose monitoring have been highly beneficial. A range of novel treatments for type I diabetes are being explored in the form of cell and immune therapies, however, optimising these therapies for routine clinical use presents an ongoing challenge. It is clear that further innovation is required in order to develop widely applicable cures for both type 1 and type 2 diseases.
This Collection aims to bring together primary research that explores recent treatment and management developments for diabetes and the development of associated methods that will improve therapy delivery.
Editors
-
Abdelilah Arredouani
Hamad Bin Khalifa University, Qatar
-
Yi-Cheng Chang
National Taiwan University Hospital, Taiwan; National Taiwan University, Taiwan; Institute of Biomedical Sciences, Taiwan
-
Yoshifumi Saisho
Saisho Diabetes Clinic, Japan
Abdelilah Arredouani is a Scientist at the Qatar Biomedical Research Institute and an assistant professor at the College of Health and Life Sciences, Hamad Bin Khalifa University. His overall research focuses on metabolic disorders, but he is especially interested in identifying biomarkers to predict and prevent prediabetes and type 2 diabetes. He is also interested understanding the mechanisms that underly the beneficial effects of glucagon-like peptide-1 receptor agonists on hepatic steatosis. Dr Arredouani has been an Editorial Board Member for Scientific Reports since 2022.
Yi-Cheng Chang is the Associate Professor of the Graduate Institute of Medical Genomics and Proteomics of National Taiwan University, the attending physician of the Department of Endocrinology and Metabolism and the vice CEO of the Bariatric and Metabolic Surgery Centor of National Taiwan University Hospital. His research focused on the genetic and translational research of diabetes mellitus, obesity, and renal disease, especially drug development. Dr. Chang has been an Editorial Board Member for Scientific Reports since 2022.
Yoshifumi Saisho is an Assistant Professor at Keio University School of Medicine. He is a member of the Fellows’ Association of the Japanese Society of Internal Medicine, the Fellows’ Association of the Japan Diabetes Society, the Japan Endocrine Society, and the Japan Atherosclerosis Society. His area of interest is Diabetology, especially beta cell dysfunction in diabetes. Dr Saisho has been an Editorial Board Member for Scientific Reports since 2019.
